Riskpilot← Back to searchSign inGet full accessUptake Bio AB
ABActiveOrg 5593946451Knut Den Stores Gata 13 EResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20220 employees
Revenue 2024
SEK 0
EBITDA margin
—
+26% vs 2023
Equity ratio
94.5%
Financial strength
Net profit 2024
SEK -1,8M
+26% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,8M | +26% |
| Net profit | SEK -1,8M | +26% |
| Total assets | SEK 562K | -80% |
| Equity | SEK 531K | -77% |
| Employees | 0 | — |
Legal name
Uptake Bio AB
Org number
5593946451
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30 augusti 2022
Share capital
SEK 28 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt, bedriva forskning, utveckling och försäljning av medicinska produkter och rättigheter, äga och förvalta fast och lös egendom samt därmed förenlig verksamhet.
Address
Knut Den Stores Gata 13 E
Email
ingvar.m.karlsson@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −2 422 | −1 784 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −2 422 | −1 784 |
| Net financials | −3 | 1 |
| Profit before tax | −2 424 | −1 784 |
| Tax | −0 | −0 |
| Net profit | −2 424 | −1 784 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 2 744 | 562 |
| Equity | 2 315 | 531 |
| Long-term debt | 0 | 0 |
| Short-term debt | 429 | 31 |
| Total debt | 429 | 31 |
EBITDA margin
-178400000.0%
This company
15.8%
Market median
-1129114024% vs market
20232024
Equity ratio
94.5%
This company
38.2%
Market median
+147% vs market
20232024
Return on equity
-336.0%
This company
18.4%
Market median
-1926% vs market
20232024
Net profit margin
-178400000.0%
This company
8.1%
Market median
-2202469236% vs market
20232024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20232024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RI Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
CA Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2024 | |
| Board of Directors | 2022 | |
| Former (5) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uptake Bio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Ingvar Lennart Karlsson | Chief Executive Officer | 0 companies |
| Cecilia Ann-Christin Malmborg Hager | Chief Executive Officer | 0 companies |
| Kjell Torsten Sjöström | Board of Directors | 0 companies |
| Tine Kold Olesen | Chairman | 0 companies |
| Marc Bennett Garnick | Board of Directors | 0 companies |
| Per-Anders Abrahamsson | Chairman | 0 companies |
| David Colpman | Board of Directors | 0 companies |
| Karl Arne Krister Borrebaeck | Board of Directors | 0 companies |
| Hans David Staffan Ulmert | Board of Directors | 0 companies |